102 related articles for article (PubMed ID: 2021930)
1. Cellular sensitization to cis-diamminedichloroplatinum(II) by novel analogues of the protein kinase C activator lyngbyatoxin A.
Basu A; Kozikowski AP; Sato K; Lazo JS
Cancer Res; 1991 May; 51(10):2511-4. PubMed ID: 2021930
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1.
Basu A; Lazo JS
Cancer Res; 1992 Jun; 52(11):3119-24. PubMed ID: 1591725
[TBL] [Abstract][Full Text] [Related]
3. Structural requirements of lyngbyatoxin A for activation and downregulation of protein kinase C.
Basu A; Kozikowski AP; Lazo JS
Biochemistry; 1992 Apr; 31(15):3824-30. PubMed ID: 1567838
[TBL] [Abstract][Full Text] [Related]
4. Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II).
Basu A; Teicher BA; Lazo JS
J Biol Chem; 1990 May; 265(15):8451-7. PubMed ID: 2341390
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells.
Basu A; Weixel K; Saijo N
Cell Growth Differ; 1996 Nov; 7(11):1507-12. PubMed ID: 8930400
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of structural analogues of lyngbyatoxin A and their evaluation as activators of protein kinase C.
Kozikowski AP; Shum PW; Basu A; Lazo JS
J Med Chem; 1991 Aug; 34(8):2420-30. PubMed ID: 1875340
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta.
Nakagawa Y; Irie K; Yanagita RC; Ohigashi H; Tsuda K; Kashiwagi K; Saito N
J Med Chem; 2006 May; 49(9):2681-8. PubMed ID: 16640328
[TBL] [Abstract][Full Text] [Related]
8. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
Jirousek MR; Gillig JR; Gonzalez CM; Heath WF; McDonald JH; Neel DA; Rito CJ; Singh U; Stramm LE; Melikian-Badalian A; Baevsky M; Ballas LM; Hall SE; Winneroski LL; Faul MM
J Med Chem; 1996 Jul; 39(14):2664-71. PubMed ID: 8709095
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin resistance is associated with deregulation in protein kinase C-delta.
Huang J; Mohanty S; Basu A
Biochem Biophys Res Commun; 2004 Apr; 316(4):1002-8. PubMed ID: 15044084
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase C isoform delta is involved in the stimulation of the Na(+)-H+ exchanger in C6 glioma cells.
Chen CC; Wu ML
Mol Pharmacol; 1995 Dec; 48(6):995-1003. PubMed ID: 8848016
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase C down-regulation, and not transient activation, correlates with melanocyte growth.
Brooks G; Wilson RE; Dooley TP; Goss MW; Hart IR
Cancer Res; 1991 Jun; 51(12):3281-8. PubMed ID: 2040003
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of cisplatin sensitivity of cisplatin-resistant human cervical carcinoma cells by bryostatin 1.
Mohanty S; Huang J; Basu A
Clin Cancer Res; 2005 Sep; 11(18):6730-7. PubMed ID: 16166454
[TBL] [Abstract][Full Text] [Related]
13. Regulation of caspase activation and cis-diamminedichloroplatinum(II)-induced cell death by protein kinase C.
Basu A; Akkaraju GR
Biochemistry; 1999 Apr; 38(14):4245-51. PubMed ID: 10194341
[TBL] [Abstract][Full Text] [Related]
14. Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis.
Grant S; Turner AJ; Freemerman AJ; Wang Z; Kramer L; Jarvis WD
Exp Cell Res; 1996 Oct; 228(1):65-75. PubMed ID: 8892972
[TBL] [Abstract][Full Text] [Related]
15. Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCdelta and discovery of an ILV analogue of improved isozyme selectivity.
Kozikowski AP; Wang S; Ma D; Yao J; Ahmad S; Glazer RI; Bogi K; Acs P; Modarres S; Lewin NE; Blumberg PM
J Med Chem; 1997 Apr; 40(9):1316-26. PubMed ID: 9135029
[TBL] [Abstract][Full Text] [Related]
16. Effect of protein kinase C activating tumor promoters on metastases formation by fibrosarcoma cells.
Isakov N; Gopas J; Priel E; Segal S; Altman A
Invasion Metastasis; 1991; 11(1):14-24. PubMed ID: 2061000
[TBL] [Abstract][Full Text] [Related]
17. Comparison of effects of bryostatins 1 and 2 and 12-O-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells.
Dale IL; Bradshaw TD; Gescher A; Pettit GR
Cancer Res; 1989 Jun; 49(12):3242-5. PubMed ID: 2720677
[TBL] [Abstract][Full Text] [Related]
18. Activation of protein kinase C and specific phosphorylation of a Mr 90,000 membrane protein of promotable BALB/3T3 and C3H/10T1/2 cells by tumor promoters.
Chida K; Hashiba H; Sasaki K; Kuroki T
Cancer Res; 1986 Mar; 46(3):1055-62. PubMed ID: 3080229
[TBL] [Abstract][Full Text] [Related]
19. A simple analogue of tumor-promoting aplysiatoxin is an antineoplastic agent rather than a tumor promoter: development of a synthetically accessible protein kinase C activator with bryostatin-like activity.
Nakagawa Y; Yanagita RC; Hamada N; Murakami A; Takahashi H; Saito N; Nagai H; Irie K
J Am Chem Soc; 2009 Jun; 131(22):7573-9. PubMed ID: 19449873
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antiproliferative effect of cis-diammine-dichloroplatinum (II) and a new anticancer agent, plasmanyl-(N-acyl)-ethanolamine, an inhibitor of protein kinase C.
Mikhaevich IS; Vlasenkova NK; Gerasimova GK
Biomed Sci; 1991; 2(6):659-64. PubMed ID: 1841636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
